Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.
Je-Yeon Yun, Yong‐Ku Kim
Psychiatry Research October 1, 2024 DOI: 10.1016/j.psychres.2024.116092 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Longitudinal Peer reviewed |
|---|---|
| Sample size | 1,983 |
| Population | Patients with treatment-resistant depression and healthy controls |
| Intervention | Ketamine |
| Dose | 0.5 mg/kg racemic ketamine and/or 0.25 mg/kg S-ketamine |
| Duration | 1–6 infusions over 2 weeks; MRI acquired 1–3 days after administration |
| Topics | Depression Ketamine Esketamine |
| Keywords | Anhedonia Magnetic resonance imaging Suicidality Thought rumination Depression treatment Brain imaging Mental health research Ketamine therapy Treatment resistance |
| Citations | 11 |
| Key findings | Brain features in limbic, salience, and fronto-parietal networks could be useful in predicting treatment-resistant depression with better response to ketamine for relief of anhedonia, thought rumination, and suicidal ideation. |
Abstract
Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic resonance imaging (MRI) studies. A comprehensive search in PubMed was performed using "ketamine AND depression AND magnetic resonance." The time span for the database queries was "Start date: 2018/01/01; End date: 2024/05/31." Total 41 original articles comprising 1,396 TRD and 587 healthy controls (HC) were included. Diagnosis of depression was made using the Structured Clinical Interview for DSM Disorders (SCID), the Mini-International Neuropsychiatric Interview (MINI), and/or the clinical assessment by psychiatrists. Patients with affective psychotic disorders were excluded. Most studies applied ketamine [0.5mg/kg racemic ketamine and/or 0.25mg/kg S-ketamine] diluted in 60cc of normal saline via intravenous infusion over 40 min one time, four times, or six times spaced 2-3 days apart over 2 weeks. Clinical outcome was defined as either remission, response, and/or percentage changes of depressive symptoms. Brain MRI of the T2*-weighted imaging (resting-state or task performance), arterial spin labeling, diffusion weighted imaging, and T1-weighted imaging were acquired at baseline and mainly 1-3days after the ketamine administration. Only the study results replicated by ≥ 2 studies and were included in the default-mode, salience, fronto-parietal, subcortical, and limbic networks were regarded as meaningful. Putative brain-based markers of treatment response to ketamine in TRD were found in the structural/functional features of limbic (subgenual ACC, hippocampus, cingulum bundle-hippocampal portion; anhedonia/suicidal ideation), salience (dorsal ACC, insula, cingulum bundle-cingulate gyrus portion; thought rumination/suicidal ideation), fronto-parietal (dorsolateral prefrontal cortex, superior longitudinal fasciculus; anhedonia/suicidal ideation), default-mode (posterior cingulate cortex; thought rumination), and subcortical (striatum; anhedonia/thought rumination) networks. Brain features of limbic, salience, and fronto-parietal networks could be useful in predicting the TRD with better response to ketamine in relief of anhedonia, thought rumination, and suicidal ideation.
Comparable studies
Other systematic reviews and meta-analyses on ketamine for depression, most cited first.